Loading...

SOHO 2026 Annual Meeting

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

Thumbnail for Phase A of the F-A-A Study: Derivation of a Bedside Functional Assessment-Age-Albumin Score for Predicting Induction Mortality in Patients With AML Receiving Low-Intensity Venetoclax-Based Therapy

AML - 927

Phase A of the F-A-A Study: Derivation of a Bedside Functional Assessment-Age-Albumin Score for Predicting Induction Mortality in Patients With AML Receiving Low-Intensity Venetoclax-Based Therapy

Rudra Narayan Swain

Poster Presenter: Rudra Narayan Swain

Thumbnail for Real-World Outcomes of Acute Myeloid Leukemia, Myelodysplasia-Related: A Single Centre Study from Pakistan

AML - 941

Real-World Outcomes of Acute Myeloid Leukemia, Myelodysplasia-Related: A Single Centre Study from Pakistan

Maryam Khan

Poster Presenter: Maryam Khan

Thumbnail for Survival Outcomes in Relation to EBMT Risk Score in Patients with Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Low- and Middle-Income Countries

AML - 946

Survival Outcomes in Relation to EBMT Risk Score in Patients with Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Low- and Middle-Income Countries

Maryam Khan

Poster Presenter: Maryam Khan

Thumbnail for A 25-Year Analysis of Leukemia and Hypertensive Disease Co-Mortality Among Older Adults in the United States, 1999-2024

AML - 947

A 25-Year Analysis of Leukemia and Hypertensive Disease Co-Mortality Among Older Adults in the United States, 1999-2024

Nuri Tamanna

Poster Presenter: Nuri Tamanna

Thumbnail for Upfront Triple Therapy With FLAG-Venetoclax Backbone in Intensive Chemotherapy-Eligible FLT3-ITD Patients With AML: Preliminary Results From a Retrospective Cohort

AML - 949

Upfront Triple Therapy With FLAG-Venetoclax Backbone in Intensive Chemotherapy-Eligible FLT3-ITD Patients With AML: Preliminary Results From a Retrospective Cohort

Mayank Soni

Poster Presenter: Mayank Soni

Thumbnail for Can Menin Inhibitors Bridge Patients to Transplant? Response Depth, MRD Negativity, and Differentiation Syndrome in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia

AML - 954

Can Menin Inhibitors Bridge Patients to Transplant? Response Depth, MRD Negativity, and Differentiation Syndrome in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia

Fnu Ashvin Rajeev Pillai

Poster Presenter: Fnu Ashvin Rajeev Pillai

Thumbnail for CDK4/6 Inhibitor Use and Risk of Therapy-Related Myeloid Neoplasms Following Chemotherapy for HR+/HER2- Breast Cancer: A Landmark Competing Risks Analysis

AML - 961

CDK4/6 Inhibitor Use and Risk of Therapy-Related Myeloid Neoplasms Following Chemotherapy for HR+/HER2- Breast Cancer: A Landmark Competing Risks Analysis

Jacqueline T Nguyen

Poster Presenter: Jacqueline T Nguyen

Thumbnail for MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

AML - 971

MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

Sai Mourya Meda

Poster Presenter: Sai Mourya Meda

Thumbnail for Venetoclax-Azacitidine Versus Intensive Chemotherapy for Induction in Childhood Acute Myeloid Leukemia: A Comparative Analysis

AML - 993

Venetoclax-Azacitidine Versus Intensive Chemotherapy for Induction in Childhood Acute Myeloid Leukemia: A Comparative Analysis

Shyam Srinivasan

Poster Presenter: Shyam Srinivasan